• 1
    Reaven G. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595607.
  • 2
    Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340: 11526.
  • 3
    Lusis A. Atherosclerosis. Nature 2000; 407: 23341.
  • 4
    DeWood M, Spores J, Notske R et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897902.
  • 5
    Zack P, Ischinger T, Aker U, Dincer B, Kennedy H. The occurrence of angiographically detected intracoronary thrombus in patients with unstable angina pectoris. Am Heart J 1984; 108: 140812.
  • 6
    Smith E, Alexander K, Massie I. Insoluble ‘fibrin’ in human aortic intima. Quantitative studies on the relationship between insoluble ‘fibrin’, soluble fibrinogen and low density lipoprotein. Atherosclerosis 1976; 23: 1939.
  • 7
    Bini A, Fenoglio J, Mesa-Tejada R, Kudryk B, Kaplan K. Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Arteriosclerosis 1989; 9: 10921.
  • 8
    Kadish J. Fibrin and atherogenesis – a hypothesis. Atherosclerosis 1979; 33: 40913.
  • 9
    Bini A, Fenoglio J, Sobel J, Owen J, Fejgl M, Kaplan K. Immunohistochemical characterization of fibrinogen, fibrin I, and fibrin II in human thrombi and atherosclerotic lesions. Blood 1987; 69: 103845.
  • 10
    Thompson W, Smith E. Atherosclerosis and the coagulation system. J Pathol 1989; 159: 97106.
  • 11
    Suwaidi J, Hamasaki S, Higano S, Nishimura R, Holmes DJ, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 94854.
  • 12
    Pasqualini L, Marchesi S, Vaudo G et al. Association between endothelial dysfunction and major cardiovascular events in peripheral vascular disease. Vasa 2003; 32: 13943.
  • 13
    Halcox J, Schenke W, Zalos G et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002; 106: 6538.
  • 14
    Corretti M, Anderson T, Benjamin E et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 25765.
  • 15
    Chowienczyk P, Cockcroft J, Ritter J. Differential inhibition by NG-monomethyl-l-arginine of vasodilator effects of acetylcholine and metacholine in human foreman in human forearm vasculature. Br J Pharmacol 1993; 110: 7368.
  • 16
    Laine H, Yki-Jarvinen H, Kirvela O et al. Insulin resistance of glucose uptake in skeletal muscle cannot be ameliorated by enhancing endothelium-dependent blood flow in obesity. J Clin Invest 1998; 101: 115662.
  • 17
    Steinberg H, Chaker H, Leaming R, Johnson A, Brechtel G, Baron A. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97: 260110.
  • 18
    Perticone F, Caravolo R, Candigliota M et al. Obesity and body fat distribution induce endothelial dysfunction by oxidative stress. Protective effect of vitamin C. Diabetes 2001; 50: 15965.
  • 19
    Balletshofer B, Rittig K, Enderle M et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 2000; 101: 17804.
  • 20
    Taylor A. Pathophysiology of hypertension and endothelial dysfunction in patients with diabetes mellitus. Endocrinol Metab Clin North Am 2001; 30: 98397.
  • 21
    Brook R, Bard R, Glazewski L et al. Effect of short-term weight loss on the metabolic syndrome and conduit vascular endothelial function in overweight adults. Am J Cardiol 2004; 93: 10126.
  • 22
    Saski S, Higashi Y, Nakagawa K et al. A low-calorie diet improves endothelium dependent vasodilatation in obese patients with essential hypertension. Am J Hypertens 2002; 15: 3029.
  • 23
    Hamdy O, Ledbury S, Mullooly C et al. Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care 2003; 26: 211925.
  • 24
    Hsueh W, Quinones M. Role of endothelial dysfunction in insulin resistance. Am J Cardiol 2003; 92(Suppl.): 10J7J.
  • 25
    Vakkilainen J, Makimattlia S, Seppala-Lindroos A et al. Endothelial dysfunction in men with small LDL particles. Circulation 2000; 102: 71621.
  • 26
    Steinberg H, Tarshoby M, Monestel R et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilatation. J Clin Invest 1997; 100: 12309.
  • 27
    Yudkin J, Stehouwer C, Emeis J, Coppack S. C-reactive protein in healthy subjects. Associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 9728.
  • 28
    Mark A, Correia M, Rahmouni K, Haynes W. Selective leptin resistance: a new concept in leptin physiology with cardiovascular implications. J Hypertens 2002; 20: 124550.
  • 29
    Ouchi N, Kihara S, Arita Y et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 24736.
  • 30
    Lind S, Marks P, Ewenstein B. Hemostatic system. In: HandinR, LuxSIV, StosselT, eds. Blood. Principles and Practice of Hematology, 2nd edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2003; 95982.
  • 31
    Juhan-Vague I, Roul C, Alessi M, Ardissone J, Heim M, Vague P. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients. Relationship with plasma insulin. Thromb Haemost 1989; 61: 3703.
  • 32
    Mansfield M, Stickland M, Grant PJ. PAI-1 concentrations in first degree relatives of patients with non-insulin dependent diabetes: metabolic and genetic associations. Thromb Haemost 1997; 77: 35761.
  • 33
    Mansfield M, Heywood D, Grant PJ. Circulating levels of factor VII, fibrinogen, and von Willebrand factor and features of insulin resistance in first degree relatives of patients with NIDDM. Circulation 1996; 94: 21716.
  • 34
    De Lange M, Snieder H, Ariens R, Spector T, Grant PJ. The genetics of haemostasis: a twin study. Lancet 2001; 357: 1015.
  • 35
    De Lange M, Snieder H, Ariens R, Andrew T, Grant PJ, Spector T. The relation between insulin resistance and hemostasis: pleiotropic genes and common environment. Twin Res 2003; 6: 110.
  • 36
    Stern M. Diabetes and cardiovascular disease. The ‘common soil’ hypothesis. Diabetes 1995; 44: 36974.
  • 37
    Kruithof E. Plasminogen activator inhibitor type 1: biochemical, biological and clinical aspects. Fibrinolysis 1988; 2: 5970.
  • 38
    Van Mejer M, Pannehoek H. Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: an update. Fibrinolysis 1995; 9: 26376.
  • 39
    Paramo J, Colucci M, Collen D, Van Der Werf F. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. BMJ 1985; 291: 5756.
  • 40
    Aznar J, Estelles A, Tormo G et al. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J 1988; 59: 53541.
  • 41
    Juhan-Vague I, Alessi M, Joly P et al. Plasma plasminogen activator inhibitor in angina pectoris. Influence of plasma insulin and acute phase response. Arteriosclerosis 1989; 9: 3627.
  • 42
    Juhan-Vague I, Pyke S, Alessi M, Jespersen J, Haverkate F, Thompson S. Fibrinolytic factors and risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996; 94: 205763.
  • 43
    Hamsten A, Defaire U, Wallidus G et al. Plasminogen activator inhibitor in plasma: a risk factor for recurrent myocardial infarction. Lancet 1987; II: 39.
  • 44
    Sakkinen P, Wahl P, Cushman M, Lewis M, Tracy R. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000; 152: 897907.
  • 45
    Juhan-Vague I, Thompson S, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome: a study of 1500 patients with angina pectoris. Arterioscler Thromb 1993; 13: 186573.
  • 46
    Vague P, Juhan-Vague I, Aillaud M et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 1986; 35: 2503.
  • 47
    Landin K, Stigendal L, Eriksson E et al. Abdominal obesity is associated with impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 1990; 39: 10448.
  • 48
    Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 1990; 227: 2738.
  • 49
    Juhan-Vague I, Vague P, Alessi M et al. Relationships between plasma insulin, triglyceride, body mass index and plasminogen activator inhibitor 1. Diab Metab 1987; 13: 3316.
  • 50
    Sundell I, Nilsson T, Hallmans G, Hellsten G, Dahlen G. Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein (a), and established cardiovascular risk factors in a North Swedish Population. Atherosclerosis 1989; 80: 916.
  • 51
    Asplund-Carlson A, Hamsten A, Wiman B, Carlson L. Relationship between plasma plasminogen activator inhibitor-1 and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men. Diabetologia 1993; 36: 81725.
  • 52
    Meigs J, Mittleman M, Nathan D et al. Hyperinsulinaemia, hyperglycaemia and impaired hemostasis. the Framingham Offspring Study. JAMA 2000; 283: 2218.
  • 53
    Festa A, D’Agostino R, Mykkanen L et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol 1999; 19: 5628.
  • 54
    Festa A, D’Agostino R, Tracy R, Haffner S. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes. Diabetes 2002; 51: 11317.
  • 55
    Festa A, Williams K, Tracy R, Wagenknecht L, Haffner S. Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation 2006; 113: 17539.
  • 56
    Vague P, Juhan-Vague I, Alessi M, Badier C, Valadier J. Metformin decreased the high plasminogen activator inhibitor capacity, plasma insulin and triglycerides in non diabetic obese subjects. Thromb Haemost 1987; 57: 3268.
  • 57
    Huisveld I, Leenen R, Van De Kooy K et al. Body composition and weight reduction in relation to antigen and activity of plasminogen activator inhibitor (PAI-1) in overweight individuals. Fibrinolysis 1990; 4: 845.
  • 58
    Gris J, Schved J, Aguilar-Martinez P, Arnaud A, Sanchez N. Impact of physical training on plasminogen activator inhibitor activity in sedentary men. Fibrinolysis 1990; 4: 978.
  • 59
    Natali A, Toschi E, Baldeweg X et al. Clustering of insulin resistance with vascular dysfunction and low grade inflammation in type 2 diabetes. Diabetes 2006; 55: 13340.
  • 60
    Sawdey S, Loskutoff D. Regulation of murine type 1 plasminogen activator inhibitor (PAI-1) gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor alpha and transforming growth factor beta. J Clin Invest 1991; 88: 134653.
  • 61
    Kooistra T, Bosma P, Tons H, Van De Berg A, Meyer P, Princen H. Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemost 1989; 62: 7238.
  • 62
    Padayattay S, Orme S, Zenobi P, Stickland M, Belchetz P, Grant P. The effects of insulin-like growth factor-1 on plasminogen activator inhibitor 1 synthesis and secretion: results from in vitro and in vivo studies. Thromb Haemost 1993; 70: 100913.
  • 63
    Mussoni L, Maderna P, Camera M et al. Atherogenic lipoproteins and PAI-1 releases by endothelial cells. Fibrinolysis 1990; 4: 7981.
  • 64
    Nordt T, Klassen K, Schneider D, Sobel B. Augmentation of synthesis of plasma plasminogen activator inhibitor 1 in arterial cells by glucose and its implications for local fibrinolysis. Arterioscler Thromb Vasc Biol 1993; 13: 18228.
  • 65
    Grant P, Kruithof E, Felley C, Felber J, Bachmann F. Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor 1 concentrations in man. Clin Sci 1990; 79: 5136.
  • 66
    Raccah D, Alessi M, Scelles V, Menard C, Juhan-Vague I, Vague P. Plasminogen activator inhibitor activity in various types of endogenous hypertriglyceridaemia. Fibrinolysis 1993; 7: 1716.
  • 67
    McGill J, Schneider D, Arfken C, Lucore C, Sobel B. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994; 43: 1049.
  • 68
    Bastard J, Pieroni L, Hainque B. Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance. Diabetes Metab Res Rev 2000; 16: 192201.
  • 69
    Schneider D, Sobel B. Synergistic augmentation of expression of plasminogen activator inhibitor 1 induced by insulin, very-low-density lipoproteins, and fatty acids. Coron Artery Dis 1996; 7: 8137.
  • 70
    Calles-Escandon J, Mirza S, Sobel B, Schneider D. Induction of hyperinsulinaemia combined with hyperglycaemia and hypertriglyceridaemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes 1998; 47: 2903.
  • 71
    Alessi M, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46: 8607.
  • 72
    Dobrovolsky A, Titaeva E. The fibrinolysis system: regulation of activity and physiologic functions of its main components. Biochemistry (Mosc) 2002; 67: 99108.
  • 73
    Norman B, Wallen P, Ranby M. Fibrinolysis mediated by tissue plasminogen activator. Disclosure of a kinetic transition. Eur J Biochem 1985; 149: 193200.
  • 74
    Nilsson T, Boman K, Bjerle P, Hallmans G, Hellsten G. von Willebrand Factor and fibrinolytic variables are differently affected in the insulin resistance syndrome. J Intern Med 1994; 235: 41923.
  • 75
    Carter A, Catto A, Grant PJ. Determinants of tPA antigen and associations with coronary artery disease and acute cerebrovascular disease. Thromb Haemost 1998; 80: 6326.
  • 76
    Chandler W, Alessi M, Aillaud M, Henderson P, Vague P, Juhan-Vague I. Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type-1(PAI-1) complex. Circulation 1997; 96: 7618.
  • 77
    Steins M, Padro T, LI C et al. Overexpression of tissue-type plasminogen activator in atherosclerotic human coronary arteries. Atherosclerosis 1999; 145: 17380.
  • 78
    Meade T, Mellows S, Brozovic M et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 5337.
  • 79
    Heinrich J, Balleisen L, Schulte H, G A, Van De Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb 1994; 14: 549.
  • 80
    Folsom A, Wu K, Rosamund W, Sharrett A, Chambless L. Prospective study of hemostatic factors and incidence of coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997; 96: 11028.
  • 81
    Scarabin P-Y, Aillaud M, Evans A et al. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10500 male participants in a prospective study of myocardial infarction. The Prime Study. Thromb Haemost 1998; 80: 74956.
  • 82
    Meade T, Ruddock V, Stirling Y, Chakrabarti R, Miller G. Fibrinolytic activity, clotting factors, and long term incidence of ischaemic heart disease in Northwick Park Heart Study. Lancet 1993; 342: 10769.
  • 83
    Folsom A, Wu K, Davis C, Conlan M, Sorlie P, Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 1991; 91: 191205.
  • 84
    Balleisen L, Assmann G, Bailey J, Epping P, Schulte H, Van De Loo J. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population – I. Baseline data on the relation to age, gender, body weight, smoking, alcohol, pill using, and menopause. Thromb Haemost 1985; 54: 4759.
  • 85
    Balleisen L, Assmann G, Bailey J, Epping P, Schulte H, Van De Loo J. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population – II. Baseline data on the relation to blood pressure, blood glucose, uric acid, and lipid fractions. Thromb Haemost 1985; 54: 7213.
  • 86
    Heywood D, Mansfield M, Grant PJ. Factor VII gene polymorphisms, factor VIIc levels and features of insulin resistance in non-insulin dependent diabetes mellitus. Thromb Haemost 1996; 75: 4016.
  • 87
    Haffner S, Stern M, Hazuda H, Mitchell B, Patterson J. Increased insulin concentrations in nondiabetic offspring of diabetic patients. N Engl J Med 1988; 319: 1297301.
  • 88
    Haffner S, Stern M, Hazuda H, Mitchell B, Patterson J. Parental history of diabetes is associated with increased cardiovascular risk factors. Arteriosclerosis 1989; 9: 92833.
  • 89
    Krolewski A, Czyzyk A, Kopczynski J, Rywik S. Prevalence of diabetes mellitus, coronary heart disease and hypertension in the families of insulin dependent and insulin independent diabetes. Diabetologia 1981; 21: 5204.
  • 90
    Stewart M, Humphriss D, Berrish T et al. Features of syndrome X in first-degree relatives of NIDDM patients. Diabetes Care 1995; 18: 10202.
  • 91
    Miller G, Walter S, Stirling Y, Thompson S, Esnouf M, Meade T. Assay of factor VII activity by two techniques: evidence for increased conversion of VII to VIIa in hyperlipidaemia, with possible implications for ischaemic heart disease. Br J Haematol 1985; 59: 24958.
  • 92
    Mitropoulos K, Miller G, Reeves B, Wilkes H, Cruickshank J. Factor VII coagulant activity is strongly associated with the plasma concentration of large lipoprotein particles in middle-aged men. Atherosclerosis 1988; 76: 2038.
  • 93
    Bruckert E, De Sousa J, Giral P et al. Interrelationship of plasma triglyceride and coagulant factor VII levels in normotriglyceridemic hypercholesterolaemia. Atherosclerosis 1989; 75: 12934.
  • 94
    Simpson H, Meade T, Stirling Y, Mann J, Chakrabarti R, Woolf L. Hypertriglyceridaemia and hypercoagulability. Lancet 1983; 1: 7869.
  • 95
    Carvalho de Sousa J, Bruckert E, Giral P et al. Coagulation factor VII and plasma triglycerides. Decreased catabolism as a possible mechanism of factor VII hyperactivity. Haemostasis 1989; 19: 12530.
  • 96
    Carvalho de Sousa J, Soria C, Ayrault-Jarrier M et al. Association between coagulation factors VII and X with triglyceride rich lipoproteins. J Clin Pathol 1988; 41: 9404.
  • 97
    Miller G, Martin J, Mitropoulos K et al. Plasma factor VII is activated by postprandial triglyceridaemia, irrespective of dietary fat composition. Atherosclerosis 1991; 86: 16371.
  • 98
    Zitoun D, Bara L, Basdevant A, Samama M. Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dylipidaemias. Arterioscler Thromb Vasc Biol 1996; 16: 7781.
  • 99
    Carvalho A, Lees R, Vaillancourt R, Cabral R, Colman R. Activation of the kallikrein system in hyperbetalipoproteinemia. J Lab Clin Med 1978; 91: 11722.
  • 100
    Seligsohn U, Osterud B, Brown S, Griffin J, Rapaport S. Activation of human factor VII in plasma and purified systems: roles of activated factor IX, kallikrein, and activated factor XII. J Clin Invest 1979; 64: 105665.
  • 101
    Wagner D. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990; 6: 21746.
  • 102
    Blann A. Increased circulating levels of von Willebrand Factor antigen in smokers may be due to lipid peroxides. Med Sci Res 1991; 19: 5356.
  • 103
    Blann A, Naqvi T, Waite M, McCollum C. von Willebrand factor and endothelial damage in essential hypertension. J Hum Hypertens 1993; 7: 10711.
  • 104
    Pedrinelli R, Giampietro O, Carmassi F et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994; 344: 148.
  • 105
    Egeberg O. Clotting factor levels in patients with coronary atherosclerosis. Scand J Clin Lab Invest 1962; 14: 2538.
  • 106
    Sugrue D, Trayner I, Thompson G et al. Coronary artery disease and haemostatic variables in heterozygous familial hypercholesterolaemia. Br Heart J 1985; 53: 2658.
  • 107
    Thompson S, Kienast J, Pyke S, Haverkate F, Van De Loo J. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 63541.
  • 108
    Jansson J, Nilsson T, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991; 66: 3515.
  • 109
    Myreng Y, Aurnes I, Hjermann I, Stormorken H, Sund T, Hellem A. von Willebrand factor and cardiovascular risk. Thromb Res 1986; 41: 86771.
  • 110
    Schmitz-Huebner U, Thompson S, Balleisen L et al. Lack of association between haemostatic variables and the presence or the extent of coronary atherosclerosis. Br Heart J 1988; 59: 28791.
  • 111
    Meade T, Chakrabarti R, Haines A, North W. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1980; 1: 10504.
  • 112
    Conlan M, Folsom A, Finch A et al. Associations of factor VIII and von Willebrand factor with age, race, sex and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities Study. Thromb Haemost 1993; 70: 3805.
  • 113
    Green D, Ruth K, Folsom A, Liu K. Hemostatic factors in the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Arterioscler Thromb 1994; 14: 68693.
  • 114
    Pinkney J, Stehouwer C, Coppack S, Yudkin J. Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes 1997; 46: s913.
  • 115
    Haffner S. Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol 2003; 92: 18j26j.
  • 116
    Doolittle R. Fibrinogen and fibrin. Annu Rev Biochem 1984; 53: 195229.
  • 117
    Lowe G, Drummond M, Third J et al. Increased plasma fibrinogen and platelet aggregates in type II hyperlipoproteinaemia. Thromb Haemost 1980; 42: 15037.
  • 118
    Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost 2003; 89: 6019.
  • 119
    Ernst E, Resch K. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 118: 95663.
  • 120
    Bonithon-Kopp C, Scarabin P-Y, Bara L, Castanier N, Jacqueson A, Roger M. Relationship between sex hormones and haemostatic factors in healthy middle-aged men. Atherosclerosis 1988; 71: 716.
  • 121
    Korsan-Bengtsen K, Wilhelmsen L, Tibblin G. Blood coagulation and fibrinolysis in a random sample of 788 men 54 years old. Relations of the variables to ‘risk factors’ for myocardial infarction. Thromb Diath Haemorrh 1972; 28: 99108.
  • 122
    Barazzoni R, Zanetti M, Davanzo G et al. Increased fibrinogen production in type 2 diabetic patients without detectable vascular complications: correlation with plasma glucagon concentrations. J Clin Endocrinol Metab 2000; 85: 31215.
  • 123
    Crook M, Couchman S, Tutt P. Plasma fibrinogen and its relationship to plasma sialic acid in non-insulin-dependent diabetes mellitus. Blood Coagul Fibrinolysis 1996; 7: 5869.
  • 124
    Donders S, Lustermans F, Van Wersch J. Glycometabolic control, lipids, and coagulation parameters in patients with non-insulin-dependent diabetes mellitus. Int J Clin Lab Res 1993; 23: 1559.
  • 125
    Avellone G, Di Garbo V, Cordova R et al. Blood coagulation and fibrinolysis in obese NIDDM patients. Diabetes Res 1994; 25: 8592.
  • 126
    Collier A, Rumley A, Rumley A et al. Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria. Diabetes 1992; 41: 90913.
  • 127
    Morishita E, Asakura H, Jokaji H et al. Hypercoagulability and high lipoprotein(a) levels in patients with type II diabetes mellitus. Atherosclerosis 1996; 120: 714.
  • 128
    Ford I, Singh T, Kitchen S, Makris M, Ward J, Preston F. Activation of coagulation in diabetes mellitus in relation to the presence of vascular complications. Diabet Med 1991; 8: 3229.
  • 129
    Fuller J, Keen H, Jarrett R et al. Haemostatic variables associated with diabetes and its complications. BMJ 1979; 2: 9646.
  • 130
    Schmitz A, Ingerslev J. Haemostatic measures in type 2 diabetic patients with microalbuminuria. Diabet Med 1990; 7: 5215.
  • 131
    Asakawa H, Tokunaga K, Kawakami F. Elevation of fibrinogen and thrombin-antithrombin III complex levels of type 2 diabetes mellitus patients with retinopathy and nephropathy. J Diabetes Complications 2000; 14: 1216.
  • 132
    Streja D, Cressey P, Rabkin S. Associations between inflammatory markers, traditional risk factors, and complications in patients with type 2 diabetes mellitus. J Diabetes Complications 2003; 17: 1207.
  • 133
    Knobl P, Schernthaner G, Schnack C et al. Thrombogenic factors are related to urinary albumin excretion rate in Type 1 (insulin-dependent) and Type 2 (non insulin-dependent) diabetic patients. Diabetologia 1993; 36: 104550.
  • 134
    Christe M, Fritschi J, Lammle B et al. Fifteen coagulation factors and fibrinolysis parameters in diabetes mellitus and in patients with vasculopathy. Thromb Haemost 1984; 52: 13843.
  • 135
    Missov R, Stolk R, Van Der Bom J et al. Plasma fibrinogen in NIDDM: the Rotterdam Study. Diabetes Care 1996; 19: 1579.
  • 136
    Ceriello A, Mercuri F, Fabbro D et al. Effect of intensive glycaemic control on fibrinogen plasma concentrations in patients with type II diabetes mellitus. Relation with beta-fibrinogen genotype. Diabetologia 1998; 41: 12703.
  • 137
    Lam T, Liu L, Janus E, Lam K, Hedley A. Fibrinogen, other cardiovascular risk factors and diabetes mellitus in Hong Kong: a community with high prevalence of type 2 diabetes mellitus and impaired glucose tolerance. Diabet Med 2000; 17: 798806.
  • 138
    Bruno G, Cavallo-Perin P, Bargero G, Borra M, D’Errico N, Pagano G. Association of fibrinogen with glycaemic control and albumin excretion rate in patients with non-insulin dependent diabetes mellitus. Ann Intern Med 1996; 125: 6537.
  • 139
    Jain A, Gupta H, Narayan S. Hyperfibrinogenaemia in patients of diabetes mellitus in relation to glycaemic control and urinary albumin excretion rate. J Assoc Physicians India 2001; 49: 22530.
  • 140
    Reid H, Vigilance J, Wright-Pascoe R, Choo-Kang E. The influence of persistent hyperglycaemia on hyperfibrinogenaemia and hyperviscosity in diabetes mellitus. West Indian Med J 2000; 49: 2814.
  • 141
    Bahru Y, Kesteven P, Alberti K, Walker M. Decreased plasminogen activator inhibitor-1 activity in newly diagnosed diabetic patients following dietary modification. Diabet Med 1993; 10: 8026.
  • 142
    Emanuele N, Azad N, Abraira C et al. Effect of intensive glycaemic control on fibrinogen, lipids, and lipoproteins. Veterans Affairs Cooperative Study in Type II Diabetes Mellitus. Arch Intern Med 1998; 158: 248590.
  • 143
    Becker A, Van Der Does F, Van Hinsbergh V, Heine R, Bouter L, Stehouwer C. Improvement of glycaemic control in type 2 diabetes: favourable changes in blood pressure, total cholesterol and triglycerides, but not in HDL cholesterol, fibrinogen, von Willebrand factor and (pro)insulin. Neth J Med 2003; 61: 12936.
  • 144
    Knobl P, Schernthaner G, Schnack C et al. Haemostatic abnormalities persist despite glycaemic improvement by insulin therapy in lean type 2 diabetic patients. Thromb Haemost 1994; 71: 6927.
  • 145
    Fanghanel G, Silva U, Sanchez-Reyes L, Sisson D, Sotres S, Torres E. Effects of metformin on fibrinogen levels in obese patients with type 2 diabetes. Rev Invest Clin 1998; 50: 38994.
  • 146
    Miller G, Esnouf M, Burgess A, Cooper J, Mitchell J. Risk of coronary heart disease and activation of factor XII in middle-aged men. Arterioscler Thromb Vasc Biol 1997; 17: 21036.
  • 147
    Kohler H, Carter A, Stickland M, Grant PJ. Levels of activated FXII in survivors of myocardial infarction - association with circulating risk factors and extent of coronary artery disease. Thromb Haemost 1998; 79: 148.
  • 148
    Schwartz M, Pizzo S, Hill R, McKee P. Human factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin. J Biol Chem 1973; 248: 1395407.
  • 149
    Kohler H, Stickland M, Ossei-Gerning N, Carter A, Grant PJ. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost 1998; 79: 813.
  • 150
    Kain K, Catto A, Grant PJ. Associations between insulin resistance and thrombotic risk factors in high-risk South Asian subjects. Diabet Med 2003; 20: 6515.
  • 151
    Mansfield M, Kohler H, Ariens R, Grant PJ. Circulating levels of coagulation factor XIII in subjects with type II diabetes and their first-degree relatives. Diabetes Care 2000; 23: 7035.
  • 152
    McKeigue P, Shah B, Marmot M. Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. Lancet 1991; 337: 3826.
  • 153
    Schmeling A, Bockholdt B, Schroder H, Geserick G. Phenotype change in polymorphic plasma proteins following liver transplantation. Exp Clin Immunogenet 1996; 13: 7883.
  • 154
    Nagy J, Henricksson P, McDonagh J. Biosynthesis of factor XIII B subunit by human hepatoma cell lines. Blood 1986; 68: 12729.
  • 155
    Dunn E, Ariens R, De Lange M et al. Genetics of fibrin clot structure: a twin study. Blood 2004; 103: 173540.
  • 156
    Gabriel D, Muga K, Boothroyd E. The effect of fibrin structure on fibrinolysis. J Biol Chem 1992; 267: 2425963.
  • 157
    Fatah K, Silveira A, Tornvall P, Karpe F, Blomback M, Hamsten A. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 1996; 76: 53540.
  • 158
    Gryglewski R, Botting R, Vane J. Mediators produced by the endothelial cell. Hypertension 1988; 12: 53048.
  • 159
    Hajek A, Joist J, Baker R, Jarrett L. Demonstration and partial characterization of insulin receptors in human platelets. J Clin Invest 1979; 63: 10605.
  • 160
    Trovati M, Anfossi G. Influence of insulin and insulin resistance on platelet and vascular smooth muscle cell function. J Diabetes Complications 2002; 16: 3540.
  • 161
    Anfossi G, Mularoni E, Burzacca S et al. Platelet resistance to nitrates in obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. Diabetes Care 1998; 21: 1216.
  • 162
    Betteridge D, El Tahir K, Reckless J, Williams K. Platelets from diabetic subjects show diminished sensitivity to prostacycline. Eur J Clin Invest 1982; 12: 3958.
  • 163
    Westerbacka J, Yki-Jarvinen H, Turpeinen A et al. Inhibition of platelet-collagen interaction. An in vivo action of insulin is abolished by insulin resistance in obesity. Arterioscler Thromb Vasc Biol 2002; 22: 16772.
  • 164
    Vinik A, Erbas T, Sun Park T, Nolan R, Pittenger G. Platelet dysfunction and type II diabetes. Diabetes Care 2001; 24: 147685.
  • 165
    Kroll M, Schafer A. Biochemical mechanisms of platelet activation. Blood 1989; 74: 118195.
  • 166
    Trovati M, Anfossi G. Insulin, insulin resistance and platelet function: similarities with insulin effects on cultured smooth muscle cells. Diabetologia 1998; 41: 60922.
  • 167
    Baldi S, Natali A, Buzzigoli G, Gavlan A, Sironi A, Ferrannini E. In vitro effect of insulin on intracellular calcium concentrations: relation to insulin resistance. Metabolism 1996; 45: 14027.
  • 168
    Ishibashi K, Kageyama S, Sakurai T et al. Inhibitory effects of insulin on intracellular calcium and aggregatory response of platelets are impaired in hypertensive subjects with insulin resistance. Hypertens Res 1997; 20: 22531.
  • 169
    Zahavi J, Betteridge J, Jones N, Galton D, Kakkar V. Enhanced in vivo platelet release reaction and malondialdehyde formation in patients with hyperlipidaemia. Am J Med 1981; 70: 5964.
  • 170
    Stegenga M, Van Der Crabben S, Levi M et al. Hyperglycaemia stimulates coagulation, whereas hyperinsulinaemia impairs fibrinolysis in healthy individuals. Diabetes 2006; 55: 180712.
  • 171
    Khechai F, Ollivier V, Bridey F et al. Effect of advanced glycation end product-modified albumin on tissue factor expression by monocytes. Arterioscler Vasc Biol 1997; 17: 288590.
  • 172
    Min C, Kang E, Yu S-H, Shinn S-H, Kim Y-S. Advanced glycation end products induce apoptosis and procoagulant activity in cultured human umbilical vein endothelial cells. Diabetes Res Clin Pract 1999; 46: 197202.
  • 173
    Enomoto M, Adachi H, Yamagashi S-I et al. Positive association of serum advanced glycation end products with thrombogenic markers in humans. Metabolism 2006; 55: 9127.
  • 174
    Osende J, Badimon J, Fuster V et al. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycaemic control. J Am Coll Cardiol 2001; 38: 130712.
  • 175
    Lieuw-A-Fa M, Van Hinsbergh V, Teerlink T et al. Increased levels of N(epsilon)-(carboxyethyl) lysine in type 1 diabetic patients with impaired renal function: correlation with markers of endothelial dysfunction. Nephrol Dial Transplant 2004; 19: 6316.
  • 176
    Dunn E, Ariens R, Grant P. The influence of type 2 diabetes on fibrin structure and function. Diabetologia 2005; 48: 1198206.
  • 177
    Dunn E, Phillipou H, Ariens R, Grant P. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 2006; 49: 107180.
  • 178
    Davi G, Ciabottoni G, Consoli A et al. In vivo formation of 8-iso-prostaglandin F and platelet activation in diabetes mellitus. Effects of improved metabolic control. Circulation 1999; 99: 2249.
  • 179
    Hangaishi M, Taguchi J, Ikari Y et al. Advanced glycation end products enhance the aggregation of human platelets in vitro. Circulation 1997; 96(Suppl. I): 665.